Prognostic potential of liver injury in patients with dilated cardiomyopathy: a retrospective study

Hai-Yan Wang1,2,3†, Yuan Huang1,2,3†, Xiao-Zhen Chen1,2,3, Zi-Lan Zhang1,2,3 and Chun Gui1,2,3*

Abstract

Background: Liver injury (LI) has been frequently observed in patients with dilated cardiomyopathy (DCM), whereas its prognostic value remains blurry. We attempted to appraise the prognostic effect of LI in patients with DCM.

Methods: This retrospective study included 523 patients with DCM. LI was defined as a threefold increase in aspartate transaminase (≥ 135 U/L) or alanine transaminase (≥ 180 U/L) or a twofold increase in total bilirubin (≥ 41 umol/L) during hospitalization. The population was segmented into non-liver injury (NLI) group and LI group based on liver function test data. To balance differences in covariates at baseline, 1:1 propensity score matching (PSM) was performed.

Results: Patients with LI had lower survival rate, compared with those with NLI (44.6% vs. 73.8%, \(P < 0.001\)). Similar results were also found in age (age > 50, 39.6% vs. 70.9%, \(P < 0.001\); age ≤ 50, 51.3% vs. 79.5%, \(P < 0.001\)) and gender stratified analysis (male, 46.2% vs. 74.4%, \(P < 0.001\); female 35.7% vs. 72.0%, \(P = 0.001\)). After PSM, the survival rate of patients with LI remained lower than those with NLI (44.6% vs. 64.1%, \(P = 0.019\)). Multivariable Cox regression analysis manifested that LI (hazard ratio [HR]: 1.692, 95% confidence interval [CI] 1.194–2.398, \(P = 0.003\); HR: 1.675, 95% CI 1.078–2.604, \(P = 0.022\), respectively) showed potent predictive effect on all-cause mortality in patients with DCM, both before and after PSM.

Conclusions: The occurrence of LI herald adverse outcomes in patients with DCM and attention to LI may be conducive to risk stratification and management.

Keywords: Dilated cardiomyopathy, Liver injury, Risk factor, Prognosis, Mortality

Background

As early as 1930, N. Jolliffe reported a phenomenon of heart failure (HF) accompanied by abnormal liver function (ALF), which predominantly referred to the elevation of bilirubin [1]. Since then, many people have devoted themselves to researching this phenomenon and disclosed that liver function indicators, such as alkaline phosphatase, γ-glutamyl-transpeptidase, transaminase and lactate dehydrogenase, not just bilirubin, may be elevated [2]. A number of recent studies identified that ALF was prevalent in acute and chronic HF and other critically ill patients, and presented unignorable prognostic value [3–7]. Nevertheless, the contribution of liver function indicators to prognosis has been mixed in numerous studies [4, 8–13]. For one thing, a post-hoc analysis of the EVEREST trial for HF with reduced ejection fraction found that reduced serum albumin (ALB) and elevated total bilirubin (TB) were associated with adverse outcomes, while aspartate transaminase (AST) and alanine transaminase (ALT) were not. For another, a study analyzing the IPH-LL trial discovered that increased liver function indicators were associated with increased mortality in patients with chronic HF [11]. Moreover, a study analyzing the EVEREST trial for patients with acute decompensated HF found that increased liver function indicators were associated with increased mortality in patients with chronic HF [12]. Despite these findings, the prognostic value of liver function indicators remains unclear. The present study aimed to explore the potential of liver injury as a prognostic marker in patients with DCM.
transaminase (ALT) were not [13]. For another, elevated AST and ALT predicted a poor prognosis of 180 days in the PROTECT study on acute HF, excluding patients with TB > 3 mg/dL or ALB < 2.8 mg/dL [4]. Despite the difference in the baseline characteristics, and inclusion and exclusion criteria were the reason for the diversity in the results, fluctuations of ALF on prognosis arouse confusion and controversy.

Of note, ALF is not entirely equivalent to liver injury (LI), that is, dysfunction of bilirubin metabolism and damage of hepatocytes [3], similar to the relationship between abnormal kidney function and kidney injury [14]. The elevation of AST and ALT is not only seen in liver diseases, but also in myopathic diseases. Similarly, the elevation of TB can also occur in extrahepatic diseases [15]. Compared with ALF, LI has clearer significance and more practical clinical utility [16]. In addition, the absolute values of AST and ALT are weakly associated with the severity or extent of LI, and their influence on prognosis is not reliable [17]. What is more, LI is a comprehensive assessment result, reflects the status of liver function and is convenient for risk stratification. Consequently, we suspected that LI may have a more dependable and robust prognostic effect than a single indicator of liver function. In a word, the impact of LI on the prognosis of patients with dilated cardiomyopathy (DCM) was blurry. We were dedicated to delineating the role of LI in patients with DCM.

Materials and methods

Study design

This retrospective study was performed at the First Affiliated Hospital of Guangxi Medical University and included 523 hospitalized DCM patients with HF admitted from August 2012 to May 2020. DCM was defined as left ventricular end-diastolic dimension (LVEDD) > 55 mm for males or > 50 mm for females and left ventricular ejection fraction (LVEF) < 45%, which cannot be explained by hypertension or coronary artery disease, and valvular or congenital heart disease were absent. The diagnosis of dilated cardiomyopathy strictly followed Chinese guidelines. LI was defined as a threefold increase in AST (≥ 135 U/L) or ALT (≥ 180 U/L) or a twofold increase in TB (≥ 41 umol/L) at any time during hospitalization [18]. Inclusion criteria were: (1) the discharge diagnosis was DCM; (2) age ≥ 18 years; (3) New York Heart Association (NYHA) class ≥ II; (4) patients admitted to our hospital for the first time. Our hospital is a regional medical center. To maintain the consistency of the characteristics of the enrolled patients, we included only patients who were discharged after comprehensive evaluation and treatment for the first time in our hospital. Exclusion criteria were: (1) chronic liver disease; (2) drug-induced liver injury; (3) acute or chronic biliary tract disease; (4) severe inflammatory or infectious diseases; (5) cardiopulmonary resuscitation; (6) new or old myocardial infarction; (7) coronary revascularization; (8) coronary artery disease complicated with myocardial ischemia; (9) acute myocarditis; (10) chronic kidney disease 5 period or need for hemodialysis; (11) heart transplantation; (12) death in hospital; (13) liver function test and cardiac ultrasound data missing; (14) traumatic patients.

All patients underwent physical examinations, blood laboratory tests, 12 lead electrocardiogram and echocardiography during the duration of hospital stay. Medical history collection, physical examinations, 12 lead electrocardiogram and medical records were finished within 8 h of admission. Blood tests of all patients were performed in our central laboratory. Cardiac ultrasonography was implemented by experienced sonographers. Echocardiographic parameters were measured according to the guidelines of the current year [19, 20], and LVEF was measured using the M-mode or modified Simpson’s method, as appropriate, and calculated using the following formula: \[ \frac{EDV (end-diastolic volume) - ESV (end-systolic volume)}{EDV} \]. The values of the hematological indicators tested in the laboratory at admission were recorded and analyzed. Estimated glomerular filtration rate (eGFR) was calculated according to the modified formula suitable for Chinese [21]. Sixteen patients or families refused to participate in this retrospective study. The primary endpoint confirmed by medical records and telephone follow-up was all-cause mortality, and there was an 8.4% loss to follow-up in our cohort. Given the retrospective study design, it was ratified by the Human Research Ethics Committee of the First Affiliated Hospital of Guangxi Medical University [NO.2022-KY-E-(280)], and informed consent was not required. The procedures had abided by the Declaration of Helsinki.

Statistical analysis

Patients were discriminated into non-liver injury (NLI) group and LI group based on liver function test data. Statistical description of quantitative variables was displayed as the mean±standard deviation or median (interquartile) according to distribution pattern. Classification variables were statistically described in number (percentage). For comparison of quantitative variables, t test or Wilcoxon rank sum test was used between the two groups, as appropriate. Qualitative data were compared using Chi-square test or Fisher exact test. Ordinal data were compared using Wilcoxon rank sum test. The significance comparison of Kaplan–Meier survival plots was tested by log-rank between the two groups. The initial
analyses were computed to test proportional hazard assumption. Relevant parameters for risk of the primary endpoint were appraised by Univariable Cox regression analysis. Subsequently, parameters with \( P < 0.05 \) were included in Multivariable Cox regression analysis, and were screened using the “forward” option. To balance differences in covariates at baseline between groups and enhance the reliability of results, propensity score matching (PSM) was performed. These covariates involved in age, sex, diabetes mellitus, NYHA class, systolic blood pressure (SBP), ALB, blood–urea–nitrogen (BUN), N-terminal pro-B-type natriuretic peptide (NT-proBNP), left atrium diameter (LAD), and renin–angiotensin system (RAS) inhibitor. Considering the ratio of two groups of patients, a 1:1 nearest-neighbor matching was implemented. All statistical analysis was executed by SPSS 23.0 and R 4.2.0. All tests were two-sided. The statistical significance was determined by \( P < 0.05 \).

## Results

### Baseline characteristics

Demographic variables, clinical and behavioral features of the population were exhibited in Table 1. 76.9% of all patients were male, and the median age of the enrolled patients was 55.0 (46.0–64.0) years. Some of the patients had a history of alcohol (43.8%) and tobacco (44.9%) use. The proportion of patients with NLI and LI were 82.4% (431/523) and 17.6% (92/523), respectively. Compared with the LI group, patients with NLI were older, had higher SBP and ALB, lower BUN and NT-proBNP level, lower proportion of NYHA IV, smaller LAD. In addition, those with NLI were less likely to be male and have diabetes mellitus. RAS inhibitor use was more common in the NLI group. Higher NYHA classification was associated with a higher proportion of patients with LI (NYHA II 5.6%, NYHA III 16.0%, NYHA IV 27.6%).

After PSM, the number of DCM patients in the LI and NLI groups was equivalent (92 vs. 92) (Table 2). Except for differences in ATS, ALT, and TB, the characteristics of baseline variables were equalized between the LI and NLI groups (all \( P > 0.05 \)).

### Primary endpoint

By the end of follow-up at a median time of 2.4 years, 164 of 523 had a primary endpoint. There were 51 cases (55.4%, 51/92) in the LI group and 113 cases (26.2%, 113/431) in the NLI group. The Kaplan–Meier survival curves testified that patients with LI had lower survival rate than those with NLI (44.6% vs. 73.8%, \( P < 0.001 \)) (Fig. 1). To confirm the robustness of the results, stratified analysis was performed. The survival rate of patients with LI was lower than that of patients with NLI in different age stratifications (age > 50, 39.6% vs. 70.9%, \( P < 0.001 \); age ≤ 50, 51.3% vs. 79.5%, \( P < 0.001 \)) (Additional file 1: Fig. S1A, B).

The prediction effect of population characteristics, comorbidities, assessment of cardiac function, hematological indicators, cardiac ultrasound data, and medication and instrument therapy on the primary endpoint are shown in Table 3 by Univariable Cox regression analysis. Body mass index, diabetes mellitus, NYHA class, SBP, BUN, AST, TB, NT-proBNP, LAD, LVEDD, LVEF, RAS inhibitor, and LI showed potent predictive value on the primary endpoint in patients with DCM in the Univariable Cox regression models before baseline adjustment using PSM (all \( P < 0.05 \)). SBP, NT-proBNP, LAD, LVEDD, LVEF, RAS inhibitor and LI played similar prognostic roles in the Univariable Cox regression models after baseline adjustment using PSM (all \( P < 0.05 \)).

Schoenfeld residuals were used to verify the relationship between hazard ratio and time. The result proved that proportional hazard assumption was applicable to LI (\( P = 0.28 \)) (Fig. 3). In the Multivariable Cox regression model, LI presented vigorous negative impact on prognosis (hazard ratio [HR]: 1.692, 95% confidence interval [CI] 1.194–2.398, \( P = 0.003 \); HR: 1.675, 95% CI 1.078–2.604, \( P = 0.022 \), respectively), both before and after PSM (Table 4).

The risk of death was approximately 1.7 times higher in LI patients than in NLI patients. However, AST, ALT, and TB did not show independent prognostic effects when they were included instead of LI in the multivariable Cox regression model. In addition, after adjusting for confounding factors, SBP (HR: 0.976, 95% CI 0.966–0.986, \( P < 0.001 \); HR: 0.973, 95% CI 0.958–0.988, \( P = 0.001 \), respectively), NT-proBNP (HR: 3.369, 95% CI 2.279–4.982, \( P < 0.001 \); HR: 2.797, 95% CI 1.586–4.932, \( P < 0.001 \), respectively) and LVEDD (HR: 1.040, 95% CI 1.022–1.058, \( P < 0.001 \); HR: 1.039, 95% CI 1.014–1.064, \( P = 0.002 \), respectively) all showed strong independent prognostic value, while LVEF (HR: 1.743, 95% CI 1.054–2.883, \( P = 0.030 \) was only independently associated with prognosis after PSM.

### Discussion

In the current study, we demonstrated for the first time that the survival rate was markedly distinguished between patients with LI and NLI in DCM, with lower survival rate in the former, which was consistent across stratified studies of different age and gender. In the PSM
Table 1  Baseline characteristics of patients categorized by liver injury

| Characteristics | All patients (n = 523) | Non-liver injury (n = 431) | Liver injury (n = 92) | P value |
|-----------------|------------------------|----------------------------|-----------------------|---------|
| Age (years)     | 55.0 (46.0–64.0)       | 56.0 (46.0–65.0)           | 51.0 (40.8–59.0)      | <0.001  |
| Male sex, n (%) | 402 (76.9)             | 324 (75.2)                 | 78 (84.8)             | 0.047   |
| Smokers, n (%)  | 235 (44.9)             | 186 (43.2)                 | 49 (53.3)             | 0.077   |
| Drinkers, n (%) | 229 (43.8)             | 183 (42.5)                 | 46 (50.0)             | 0.186   |
| BMI (kg/m²)     | 23.1 (20.6–26.0)       | 23.3 (20.8–26.0)           | 22.7 (19.9–25.0)      | 0.111   |
| Comorbidity, n (%) |                |                            |                       |         |
| Acute heart failure | 406 (77.6)         | 329 (76.3)                 | 77 (83.7)             | 0.124   |
| Coronary artery disease | 30 (5.7)          | 28 (6.5)                   | 2 (2.2)               | 0.106   |
| Hypertension    | 80 (15.3)             | 71 (16.5)                  | 9 (9.8)               | 0.106   |
| Diabetes mellitus | 76 (14.5)           | 56 (13.0)                  | 20 (21.7)             | 0.031   |
| Atrial fibrillation | 97 (18.5)          | 77 (17.9)                  | 20 (21.7)             | 0.386   |
| NYHA class, n (%) |                  |                            |                       | <0.001  |
| II              | 125 (23.9)            | 118 (27.4)                 | 7 (7.6)               |         |
| III             | 213 (40.7)            | 179 (41.5)                 | 34 (37.0)             |         |
| IV              | 185 (35.4)            | 134 (31.1)                 | 51 (55.4)             |         |
| SBP (mmHg)      | 114.0 (102.0–126.0)   | 116.0 (103.0–128.0)        | 106.0 (97.0–117.0)    | <0.001  |
| DBP (mmHg)      | 75.0 (68.0–86.0)      | 76.0 (66.0–86.0)           | 75.0 (69.0–84.0)      | 0.788   |
| Red blood cell (× 10¹²/L) | 4.73 (4.34–5.17)  | 4.73 (4.31–5.13)           | 4.91 (4.47–5.36)      | 0.083   |
| Hemoglobin (g/L) | 136.8 (126.6–147.7)   | 136.6 (126.0–147.1)        | 138.1 (128.2–150.5)   | 0.232   |
| Albumin (g/L)   | 38.50 ± 4.62          | 38.71 ± 4.65               | 37.55 ± 4.33          | 0.029   |
| AST (U/L)       | 31.0 (23.0–43.0)      | 29.0 (23.0–39.0)           | 47.0 (31.3–137.5)     | <0.001  |
| ALT (U/L)       | 31.0 (19.0–51.0)      | 30.0 (18.0–45.0)           | 53.5 (29.3–180.0)     | <0.001  |
| Total bilirubin (μmol/L) | 17.0 (11.0–28.1) | 14.2 (9.9–21.6)           | 46.1 (33.5–56.4)      | <0.001  |
| BUN (mmol/L)    | 6.90 (5.42–8.77)      | 6.64 (5.35–8.52)           | 8.02 (5.83–11.14)     | <0.001  |
| eGFR (mL/min/1.73 m²) | 91.6 (74.6–110.5) | 91.4 (75.7–109.8)       | 92.3 (72.2–118.8)     | 0.705   |
| NT-proBNP (pg/mL) | 3723 (1766–7065) | 3301 (1609–6481)         | 6481 (2689–12,152)    | <0.001  |
| QRS duration (ms) | 106.0 (98.0–122.0) | 106.0 (96.0–122.0)       | 107.0 (98.5–118.0)    | 0.687   |
| LAD (mm)        | 46.0 (42.0–51.0)      | 46.0 (41.0–50.0)           | 49.5 (44.0–53.0)      | <0.001  |
| LVEDD (mm)      | 70.0 (64.0–76.0)      | 69.0 (64.0–76.0)           | 72.0 (65.0–78.0)      | 0.118   |
| LVEF (%)        | 33.0 (27.0–38.0)      | 33.0 (27.0–38.0)           | 31.0 (25.0–38.0)      | 0.281   |
| Drug therapy, n (%) |                |                            |                       |         |
| RAS inhibitor   | 460 (88.0)            | 389 (90.3)                 | 71 (77.2)             | <0.001  |
| ACEI/ARB        | 408 (78.0)            | 343 (79.6)                 | 65 (70.7)             | 0.060   |
| ARNI            | 52 (9.9)              | 46 (10.7)                  | 6 (6.5)               | 0.227   |
| Beta-blocker    | 471 (90.1)            | 385 (89.3)                 | 86 (93.5)             | 0.227   |
| Diuretic        | 520 (99.4)            | 428 (99.3)                 | 92 (100.0)            | 1.000   |
| Spironolactone  | 501 (95.8)            | 416 (96.5)                 | 85 (92.4)             | 0.086   |
| Digoxin         | 415 (79.3)            | 340 (78.9)                 | 75 (81.5)             | 0.571   |
| ICD/CRT, n (%)  | 23 (4.4)              | 19 (4.4)                   | 4 (4.3)               | 1.000   |

Data are displayed as the mean ± SD (standard deviation), or median (interquartile range), or number (percentage). BMI data were missing in 9 cases. Electrocardiogram were missing in 42 cases.

BMI: body mass index; NYHA: New York Heart Association; SBP: systolic blood pressure; DBP: diastolic blood pressure; AST: aspartate transaminase; ALT: alanine transaminase; BUN: blood–urea–nitrogen; eGFR: estimated glomerular filtration rate; NT-proBNP: N-terminal pro-B-type natriuretic peptide; LAD: left atrium diameter; LVEDD: left ventricular end-diastolic dimension; LVEF: left ventricular ejection fraction; RAS: renin–angiotensin system; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor nephrilysin inhibitor; ICD: implantable cardioverter defibrillator; CRT: cardiac resynchronization therapy
cohort, the survival rate was still lower in patients with LI. LI emerged powerfully negative effect on survival, regardless of adjustment for potential confounders. After PSM, the same results still hold. Using PSM method, the influence of potential covariates was eliminated, the comparability between the two groups of patients was higher, and the reliability of the results was strengthened. The majority of patients included in previous studies had only slight ALF (liver function indicators < 2–3 times the upper limit of normal) [4, 6, 8, 9, 13], and the value of LI has not been thoroughly affirmed. In clinical setting, there is a significant difference between the treatment and management of patients with slight ALF and LI. Our research focusing on LI is beneficial to clinical work and makes up for the shortcomings of previous studies. This is the first literature on the prognostic potential of LI in

| Characteristics                  | All patients (n = 184) | Non-liver injury (n = 92) | Liver injury (n = 92) | P value |
|----------------------------------|------------------------|---------------------------|-----------------------|---------|
| Age (years)                      | 51.0 (38.0–58.0)       | 49.0 (37.3–57.8)          | 51.0 (40.8–59.0)      | 0.434   |
| Male sex, n (%)                  | 149 (81.0)             | 71 (77.2)                 | 78 (84.8)             | 0.189   |
| Smokers, n (%)                   | 97 (52.7)              | 48 (52.2)                 | 49 (53.3)             | 0.883   |
| Drinkers, n (%)                  | 86 (46.7)              | 40 (43.5)                 | 46 (50.0)             | 0.375   |
| BMI (kg/m²)                      | 22.7 (20.0–25.9)       | 23.0 (20.2–26.5)          | 22.7 (19.9–25.0)      | 0.480   |
| Comorbidity, n (%)               |                        |                           |                       |         |
| Acute heart failure              | 157 (85.3)             | 80 (87.0)                 | 77 (83.7)             | 0.532   |
| Coronary artery disease          | 6 (3.3)                | 4 (4.3)                   | 2 (2.2)               | 0.682   |
| Hypertension                     | 20 (10.9)              | 11 (12.0)                 | 9 (9.8)               | 0.636   |
| Diabetes mellitus                | 40 (21.7)              | 20 (21.7)                 | 20 (21.7)             | 0.100   |
| Atrial fibrillation              | 39 (21.2)              | 19 (20.7)                 | 20 (21.7)             | 0.857   |
| NYHA class, n (%)                |                        |                           |                       | 0.596   |
| II                               | 14 (7.6)               | 7 (7.6)                   | 7 (7.6)               |         |
| III                              | 72 (39.1)              | 38 (41.3)                 | 34 (37.0)             |         |
| IV                               | 98 (53.3)              | 47 (51.1)                 | 51 (55.4)             |         |
| SBP (mmHg)                       | 106.0 (97.0–117.8)     | 106.0 (98.0–118.0)        | 106.0 (97.0–117.0)    | 0.666   |
| DBP (mmHg)                       | 74.0 (66.0–84.0)       | 71.0 (64.0–84.3)          | 75.0 (69.0–84.0)      | 0.111   |
| Laboratory data                  |                        |                           |                       |         |
| Red blood cell (× 10¹²/L)        | 4.75 (4.29–5.23)       | 4.69 (4.19–5.03)          | 4.91 (4.47–5.36)      | 0.070   |
| Hemoglobin (g/L)                 | 137.0 (128.4–149.9)    | 137.0 (128.9–149.0)       | 138.1 (128.2–150.5)   | 0.801   |
| Albumin (g/L)                    | 37.1 ± 4.46            | 36.71 ± 4.56              | 37.55 ± 4.33          | 0.202   |
| AST (U/L)                        | 37.0 (28.0–62.0)       | 33.0 (23.0–43.0)          | 47.0 (31.3–137.5)     | < 0.001 |
| ALT (U/L)                        | 38.5 (24.0–88.8)       | 31.0 (20.3–48.8)          | 53.5 (29.3–180.0)     | < 0.001 |
| Total bilirubin (μmol/L)         | 28.6 (16.8–46.2)       | 17.7 (10.9–23.8)          | 46.1 (33.5–56.4)      | < 0.001 |
| BUN (mmol/L)                     | 7.73 (5.65–10.69)      | 7.38 (5.53–9.66)          | 8.02 (5.83–11.14)     | 0.123   |
| eGFR (mL/min/1.73 m²)            | 89.9 (70.9–114.5)      | 88.7 (70.4–112.8)         | 92.3 (72.2–118.8)     | 0.484   |
| NT-proBNP (pg/mL)                | 6051 (2881–10,139)     | 5779 (2916–9574)          | 6481 (2689–12,152)    | 0.478   |
| QRS duration (ms)                | 106.0 (98.0–118.0)     | 106.0 (96.0–121.0)        | 107.0 (98.5–118.0)    | 0.443   |
| Cardiac ultrasound data          |                        |                           |                       |         |
| LAD (mm)                         | 48.0 (43.3–53.0)       | 46.5 (43.0–52.0)          | 49.5 (44.0–53.0)      | 0.173   |
| LVEDD (mm)                       | 71.0 (65.0–77.0)       | 70.5 (66.0–76.0)          | 72.0 (65.0–78.0)      | 0.546   |
| LVEF (%)                         | 31.0 (25.0–37.0)       | 31.0 (24.6–37.0)          | 31.0 (25.0–38.0)      | 0.816   |
| Drug therapy, n (%)              |                        |                           |                       |         |
| RAS inhibitor                    | 144 (78.3)             | 73 (79.3)                 | 71 (77.2)             | 0.721   |
| Beta-blocker                     | 169 (91.8)             | 83 (90.2)                 | 86 (93.5)             | 0.419   |
| Diuretic                         | 184 (100.0)            | 92 (100.0)                | 92 (100.0)            | 1.000   |
| Spironolactone                   | 174 (94.6)             | 89 (96.7)                 | 85 (92.4)             | 0.193   |
| Digoxin                          | 155 (84.2)             | 80 (87.0)                 | 75 (81.5)             | 0.312   |
| ICD/CRT, n (%)                   | 8 (4.3)                | 4 (4.3)                   | 4 (4.3)               | 1.000   |
Fig. 1 Kaplan–Meier curves estimated the occurrence of the primary outcome in patients with and without liver injury. In this plot, the survival probability is shown over time for two groups: non-liver injury and liver injury. The curves are separated by a clear difference, with the liver injury group having a lower survival probability. The p-value is 0.001, indicating a statistically significant difference.

Fig. 2 Kaplan–Meier curves estimated the occurrence of the primary outcome in patients with and without liver injury after propensity score matching. Similar to Fig. 1, this plot also shows the survival probability over time for the two groups, with distinct curves for non-liver injury and liver injury. The p-value is 0.019, further supporting the significance of the difference between the groups.
| Variable                  | Before baseline adjustment using PSM | After baseline adjustment using PSM |
|--------------------------|--------------------------------------|-----------------------------------|
|                          | HR        | 95% CI     | P value | HR        | 95% CI     | P value |
| Age                      | 1.005     | 0.993–1.018 | 0.383   | 1.006     | 0.990–1.023 | 0.435   |
| Male                     | 1.049     | 0.732–1.503 | 0.796   | 1.075     | 0.624–1.854 | 0.794   |
| BMI                      | 0.943     | 0.904–0.984 | 0.007   | 0.965     | 0.914–1.019 | 0.199   |
| Hypertension             | 0.789     | 0.489–1.272 | 0.331   | 0.827     | 0.399–1.714 | 0.609   |
| Diabetes mellitus        | 1.525     | 1.025–2.268 | 0.037   | 1.354     | 0.817–2.242 | 0.239   |
| Atrial fibrillation      | 0.988     | 0.665–1.468 | 0.953   | 0.779     | 0.451–1.343 | 0.369   |
| NYHA class IV/II–III     | 1.556     | 1.144–2.118 | 0.005   | 1.405     | 0.909–2.173 | 0.126   |
| SBP                      | 0.972     | 0.963–0.982 | <0.001  | 0.972     | 0.957–0.987 | <0.001  |
| BUN                      | 1.064     | 1.029–1.101 | <0.001  | 1.036     | 0.997–1.077 | 0.074   |
| eGFR ≥ 60 mL/min/1.73 m² | 0.649     | 0.402–1.047 | 0.076   | 0.813     | 0.450–1.471 | 0.494   |
| AST                      | 1.002     | 1.000–1.004 | 0.021   | 1.000     | 0.998–1.003 | 0.805   |
| ALT                      | 1.001     | 1.000–1.002 | 0.168   | 1.000     | 0.998–1.001 | 0.773   |
| Total bilirubin          | 1.005     | 1.002–1.008 | 0.004   | 1.001     | 0.997–1.005 | 0.610   |
| Lg (NT-proBNP)           | 3.533     | 2.451–5.093 | <0.001  | 2.698     | 1.566–4.649 | <0.001  |
| QRS                      | 1.005     | 1.000–1.010 | 0.071   | 1.006     | 0.999–1.013 | 0.096   |
| LAD                      | 1.041     | 1.021–1.062 | <0.001  | 1.028     | 1.001–1.056 | 0.041   |
| LVEDD                    | 1.044     | 1.027–1.061 | <0.001  | 1.036     | 1.014–1.059 | 0.001   |
| LVEF < 35%               | 1.637     | 1.173–2.283 | 0.004   | 2.000     | 1.228–3.260 | 0.005   |
| RAS inhibitor            | 0.548     | 0.368–0.814 | 0.003   | 0.587     | 0.365–0.943 | 0.028   |
| Beta-blocker             | 0.900     | 0.563–1.438 | 0.660   | 0.964     | 0.464–2.004 | 0.922   |
| Spironolactone           | 0.761     | 0.374–1.549 | 0.451   | 0.699     | 0.283–1.727 | 0.438   |
| ICD/CRT                  | 0.837     | 0.393–1.786 | 0.646   | 1.137     | 0.416–3.108 | 0.802   |
| Liver injury             | 2.583     | 1.855–3.597 | <0.001  | 1.677     | 1.082–2.599 | 0.021   |

Fig. 3 Test of the proportional hazard assumption of Cox regression for liver injury
DCM, and the results have positive implications for the stratified management of patients with DCM.

When AST, ALT and TB were included as a continuous variable in the final model, they did not show an independent predictive value for prognosis in patients with DCM. The reason for this may be that in this study, the changes of liver function indicators within the normal range or slight increase had no potential clinical implication. Only when LI occurred, the prognostic value of liver function indicators was highlighted. Although previous studies [4, 13] do not entirely support the ideas presented here, the omission of vital measures such as NT-proBNP [4], LAD and LVEDD [13] from the final models may have weakened the applicability of their conclusions to patients with DCM.

There are no epidemiological studies on AFL or LI in outpatients with cardiovascular disease. A reported ALF occurs in 1–4% of asymptomatic patients [15]. We speculated that LI in outpatients with DCM has extremely low incidence and is not easily perceived. Moreover, whether the LI in outpatients with DCM is related to drugs or infectious diseases requires a comprehensive and complex evaluation process. In conclusion, we considered that LI in inpatients compared with LI in outpatients is easier to be found and judged, and has higher application value.

With the early diagnosis and etiological intervention, the development of comprehensive drug therapy and the improvement of device therapy, the survival rate of DCM patients has been considerably improved [22]. During a median follow-up of 2.4 years, approximately 31.4% of patients with DCM had a primary endpoint event in our study, which is apparently extremely high. The high mortality rate can be explained by the following reasons. First, according to the inclusion criteria and Chinese guidelines, patients with NYHA I or LVEF ≥ 45% were not included, who have better cardiac function and a favorable prognosis. Second, the rate of device therapy was low (4.4%). Third, because of the retrospective design, there was an 8.4% loss to follow-up in our cohort.

The liver is supplied by both the portal vein (70%) and the hepatic artery (30%), and its blood flow accounts for about one-fifth to one-quarter of the cardiac output [23]. It is involved in the uptake and transformation of indirect bilirubin as well as the excretion of direct bilirubin. Under the condition of hypoxia, the ability of the liver to uptake, transformation and excretion of bilirubin is weakened, which will inevitably lead to the rise of TB [24, 25]. In addition, the increase in TB may be due to hemolysis caused by congestive liver [26]. Diminished hepatic blood flow can be caused by a compensatory increase in vascular resistance sparked by reduced cardiac output and mesenteric vasoconstriction by an activated renin–angiotensin system [27, 28]. When rats developed intestinal ischemia–reperfusion injury, portal venous blood flow to the liver decreased by 66% during ischemia and hepatic arterial blood flow decreased by 80% during reperfusion, resulting in transient acute liver dysfunction (decreased bile secretion, increased ALT, and reduced ATP in liver tissue) [29]. In a model of systemic hypoperfusion induced by cardiac tamponade in pigs, decreased aortic blood flow triggered depletion of the hepatic artery buffering response, leading to liver dysfunction without evidence of cellular damage [30]. At present, the possible reason for liver dysfunction covers hepatic venous congestion secondary to right ventricular dysfunction, ischemia attributed to reduced hepatic blood flow, and hypoxemia attributed to by hepatic artery hypoxia [31]. It is generally accepted that transaminase abnormalities were dominated by hepatocyte necrosis caused by ischemia and hypoxia, while cholestasis caused by hepatic congestion was accompanied by an increase.

Table 4 Multivariable Cox regression analyses for all-cause mortality in patients with dilated cardiomyopathy

| Variable | Before baseline adjustment using PSM | | After baseline adjustment using PSM | |
|----------|-------------------------------------|--------|-------------------------------------|--------|
|          | HR 95% CI   | P value | HR 95% CI   | P value |
| SBP      | 0.976 0.966–0.986 | <0.001 | 0.973 0.958–0.988 | 0.001 |
| LVEDD    | 3.369 2.279–4.982 | <0.001 | 2.797 1.586–4.932 | <0.001 |
| LVEF < 35% | 1.040 1.022–1.058 | <0.001 | 1.039 1.014–1.064 | 0.002 |
| Liver injury | 1.692 1.194–2.398 | 0.003 | 1.675 1.078–2.604 | 0.022 |
| AST      | Unselected  | Unselected | Unselected  | Unselected |
| ALT      | Unselected  | Unselected | Unselected  | Unselected |
| TB       | Unselected  | Unselected | Unselected  | Unselected |

Model was adjusted for BMI, diabetes mellitus, NYHA class, BUN, LAD, LVEF and RAS inhibitor before PSM
Model was adjusted for LAD, and RAS inhibitor after PSM
in TB, but it is impractical to definitely distinguish between the two mechanisms, as they commonly coexist and mutually exacerbate the detrimental effects on the liver [31, 32]. ALF was not only observed in hypotensive patients, but also applied to the anoxic condition of the person with normal BP [33]. Furthermore, Rossello X et al. found that normal blood pressure did not equate to no hypoperfusion in acute HF, and patients with higher SBP were less likely to be accompanied by hypoperfusion [34]. Thus, it was reasonable for the patient with LI to have normal but lower SBP.

DCM is characterized by enlarged LVEDD and reduced LVEF, and its underlying molecular mechanism involves activation of the neurohumoral system, which forms the pathophysiological basis of LI occurrence [35, 36]. The effect of LI on prognosis of patients with DCM should be considered from AST, ALT and TB. Many studies have verified that AST, ALT and TB were associated with increased right atrial pressure, pulmonary wedge pressure, and central venous pressure, as well as decreased cardiac index [37–40]. This implied that the presence of LI may be a sign of tissue hypoperfusion or systemic congestion. Although proxies for congestion (i.e., NT-proBNP) and perfusion (i.e., SBP and LVEF) were incorporated into the final multivariate model, LI may represent hemodynamic changes that cannot be captured by traditional measures. Given that NT-proBNP is a serological marker for diagnosing HF and reflecting ventricular wall tension [41], patients with LI had higher NT-proBNP and may have more severe circulatory congestion. Therefore, it was not surprising that there was a higher proportion of NYHA IV in patients with LI. LI exhibited irreplacability in terms of prognosis, which indicated that LI not only reflected the temporary alterations of hemodynamics of DCM, but also reflected the potential pathological state and disease development stage of DCM, affecting the long-term prognosis of DCM patients. Compared with invasive hemodynamic monitoring, liver function testing is convenient, inexpensive, and acceptable, which provides the possibility of repeated testing and clinical follow-up.

The protective effect of higher SBP was consistent with previous studies [42, 43], and the underlying mechanism may be that patients with higher SBP had better tissue perfusion and cardiac function. Meanwhile, NT-proBNP consistently presented prognostic value that cannot be ignored [44]. The negative effect of LVEDD in this study was not surprising, since it had been demonstrated that expansion of LVEDD increased the risk of HF and sudden cardiac death [45, 46]. Interestingly, LVEF was not included in the final model before PSM, which may be due to the interference of confounding factors. Nonetheless, LVEF remained an irreplaceable prognostic factor after PSM.

Vincenzo Nuzzi et al. found that permanent atrial fibrillation (AF) had a similar effect on the prognosis of DCM patients as LI in this paper, while paroxysmal or persistent AF presented neutral results [47]. However, the adverse effects of permanent AF were not evident in our study. The reasons may be as follows: on one hand, with the retrospective data, we cannot make a precise distinction between permanent, paroxysmal, and persistent AF. Consequently, studies mixing the above three may influence the presentation of the results. On the other hand, whether patients underwent radiofrequency ablation after discharge and whether sinus rhythm was restored, which were not available and may also have interfered with the results. Kidney function included as a categorical variable (eGFR ≥ 60 mL/min/1.73 m²) in univariate COX analysis was not significantly associated with the prognosis of patients with DCM, which may be due to the exclusion of patients with severe chronic kidney disease. Furthermore, the use of RAS inhibitor may improve kidney function, thus affecting its prognostic effect on patients with DCM. More importantly, the vast majority of patients did not have chronic kidney disease and the decrease in eGFR may be a transient phenomenon.

As far as we know, the reverse action mechanism of cardiogenic LI on the heart may include the following three aspects. First, the development of LI may promote the release of inflammatory factors, activate cell signaling pathways, and cause myocardial dysfunction, similar to those found in cirrhotic cardiomyopathy [48]. Second, the possible changes in the metabolic function of hepatocytes alter the medication metabolism process and influence its efficacy [49]. Finally, the liver is a transit point for material metabolism, and LI may affect its energy supply to the heart and other vital organs [50].

We acknowledge that this report had some limitations. The general flaws of retrospective studies were also not immune to this study. First, in addition to liver function indicators, we had no additional liver morphological, pathological, and hemodynamic information to adequately assess the severity of LI and its impact on prognosis. Second, we did not analyze the duration and recovery of LI, and these data may have different effects on the results. Third, the absence of myocardial injury-specific markers prevented us from reliably ruling out the role of myocardial injury in the outcome. Fourth, the lack of data on the assessment of right heart function prevented us from considering all factors that might have influenced the results. Finally, variations in patient medication and device therapy were not recorded during follow-up. This may constitute a latent factor that interfered
with the results, even if the baseline levels of drugs were balanced.

**Conclusions**

The results of this study, which incorporated numerous patients with long-term follow-up, revealed that the occurrence of LI predicted a potentially bad prognosis in patients with DCM.

Attention to LI is beneficial to identify high-risk DCM patients and guide the next management.

**Abbreviations**

ALF: Abnormal liver function; LI: Liver injury; ALB: Albumin; TB: Total bilirubin; AST: Aspartate transaminase; ALT: Alanine transaminase; HF: Heart failure; DCM: Dilated cardiomyopathy; LAD: Left atrium diameter; LVEDD: Left ventricular end-diastolic diameter; LVEF: Left ventricular ejection fraction; NYHA: New York Heart Association; PSM: Propensity score matching; SBP: Systolic blood pressure; BUN: Blood-urea-nitrogen; NT-proBNP: N-terminal pro-B-type natriuretic peptide; eGFR: Estimated glomerular filtration rate; RAS: Renin–angiotensin system; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; ARNI: Angiotensin receptor neprilysin inhibitor.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s40001-022-00876-9.

**Additional file 1:** Table S1. Mean dose of drug during hospitalization in the study population. Table S2. Cause of death in the study population.

**Figure S1.** Kaplan–Meier curves of stratified analysis showed the occurrence of the primary outcome in patients with and without liver injury. (A) age ≤ 50 years; (B) age > 50 years; (C) male; (D) female.

**Acknowledgements**

Not applicable.

**Author contributions**

HYW and CG designed the study. HYW analyzed the data and wrote the manuscript. YH participated in the study design, data analysis, editing. CG supervised the overall study and contributed to editing and review of the manuscript. XZC and ZLZ were responsible for collecting, sorting and statistical analysis. HYW is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

**Funding**

This work was supported by Innovative Research Team Project of Guangxi Natural Science Foundation (Grant No. 2018GXNSFDA281006) and Guangxi Natural Science Foundation Project (Grant No. 2020GXNSFBA297014).

**Availability of data and materials**

The supporting data can be acquired via the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The study protocol was approved by the Human Research Ethics Committee of the First Affiliated Hospital of Guangxi Medical University (No. 2022-KY-E-(280)) and the requirement for informed consent was waived because of the retrospective nature of the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the Helsinki declaration and its later amendments or comparable ethical standards.

**Consent for publication**

All the authors consented for publication.

**Competing interests**

The authors declare no competing interests.

**Author details**

1Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyang Road, Nanning 530021, Guangxi, China.

2Guangxi Key Laboratory Base of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention, No. 6, Shuangyang Road, Nanning 530021, Guangxi, China.

3Guangxi Clinical Research Center for Cardio-Cerebrovascular Diseases, No. 6, Shuangyang Road, Nanning 530021, Guangxi, China.

**Received: 23 August 2022 Accepted: 23 October 2022**

**Published online:** 08 November 2022

**References**

1. Jolliffe N. Liver function in congestive heart failure. J Clin Invest. 1930;8(3):419–33. https://doi.org/10.1172/JCI100272.

2. Cagli K, Basar FN, Tok D, Turak O, Basar O. How to interpret liver function tests in heart failure patients? Turk J Gastroenterol. 2015;26(3):197–203. https://doi.org/10.5152/tjg.2015.0086.

3. Horvatits T, Drolz A, Trauner M, Fuhmann V. Liver injury and failure in critical illness. Hepatology. 2019;70(6):2204–15. https://doi.org/10.1002/hep.31824.

4. Biegus J, Hillege HL, Postmus D, Valente MA, Bloomfield DM, Cleland JG, et al. Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. Eur J Heart Fail. 2016;18(7):850–9. https://doi.org/10.1002/ejhf.532.

5. Biegus J, Zymiliński R, Sokolski M, Nawrocka S, Siwotowski P, Szachniewicz J, et al. Liver function tests in patients with acute heart failure. Pol Arch Med Wewn. 2012;122(10):471–9. https://doi.org/10.20452/pamw.1413.

6. Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeffer MA, Swedberg K, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Cardesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009;11(2):170–7. https://doi.org/10.1093/europace/einp031.

7. Batin P, Wickens M, McEntegart D, Fullwood L, Cowley AJ. The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J. 1995;16(11):1613–8. https://doi.org/10.1093/europace/16.11.1613.

8. Liang W, He X, Wu D, Xue R, Dong B, Owusu-Agyeman M, et al. Prognostic implication of liver function tests in heart failure with preserved ejection fraction without chronic hepatic diseases: insight from TOPCAT Trial. Front Cardiovasc Med. 2021;8:618816. https://doi.org/10.3389/fcm.2021.618816.

9. Suzuki K, Claggett B, Minamisawa M, Packer M, Zile MR, Rouleau J, et al. Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2020;22(9):1662–71. https://doi.org/10.1002/ejhf.1853.

10. van Deursen VM, Edwards C, Cotter G, Davison BA, Damman K, Teerlink JR, et al. Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure study. J Card Fail. 2014;20(6):407–13. https://doi.org/10.1016/j.cardfail.2014.03.003.

11. Chintanabolina J, Haner MS, Sethi A, Patel N, Tanyous W, Lalos A, et al. Serum bilirubin as a prognostic marker in patients with acute decompensated heart failure. Korean J Intern Med. 2013;28(3):300–5. https://doi.org/10.3904/kjim.2013.28.3.300.

12. Poezl G, Ess M, Musser-Seeber C, Pachinger O, Frick M, Ulmer H. Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. Eur J Clin Invest. 2012;42(2):153–63. https://doi.org/10.1111/j.1365-2362.2011.05273.x.

13. Ambrosy AP, Vaduganathan M, Huffman MD, Khan S, Kvasny MJ, Fought AJ, et al. Clinical course and predictive value of liver function test...
tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail. 2012;14(3):302–11. https://doi.org/10.1002/ejhf.hfs007.

14. Chawla LS, Bellomo R, Bhooar A, Goldstein SL, Siew ED, Bagshaw SM, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13(4):241–57. https://doi.org/10.1038/nrneph.2017.2.

15. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123(4):1367–84. https://doi.org/10.1016/s0016-5085(02)00601-9.

16. Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. Practice Parameters Committee of the American College of G. ACG Clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021;116(5):878–98. https://doi.org/10.14309/ajg.0000000000001259.

17. Krier M, Ahmed A. The asymptomatic outpatient with abnormal liver function tests. Clin Liver Dis. 2009;13(2):167–77. https://doi.org/10.1016/j.cld.2009.02.001.

18. Zhang SS, Dong L, Wang GM, Tian Y, Ye XF, Zhao Y, et al. Progressive liver injury and increased mortality risk in COVID-19 patients: a retrospective cohort study in China. World J Gastroenterol. 2021;27(9):835–53. https://doi.org/10.3748/wjg.v27.i9.835.

19. Lang RM, Badano LP, Mor-Avi V, Alfieri O, Armstrong A, Emande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14. https://doi.org/10.1016/j.echo.2014.10.003.

20. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–63. https://doi.org/10.1016/j.echo.2005.10.005.

21. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimation equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2008;19(1):2937–44. https://doi.org/10.1681/asn.2006040368.

22. Merlo M, Cannatà A, Gobbo M, Stolfo D, Elliott PM, Sinagra G. Evolving chemistries tests. Gastroenterology. 2002;123(4):1367–84. https://doi.org/10.1016/s0016-5085(02)00601-9.

23. Koehnede Gonzalez AK, Lefkowitch JH. Heart disease and the liver: pathologic evaluation. Gastroenterol Clin N Am. 2018;47(2):241–55. https://doi.org/10.1016/j.gtc.2017.01.012.

24. Birrer R, Takuda Y, Takara T. Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med. 2007;46(1):1063–70. https://doi.org/10.1016/j.imn.2006.05.009.

25. Rossello X, Bueno H, Gil V, Jacob J, Martin-Sanchez FJ, Llorens P, et al. Synergistic impact of systolic blood pressure and perfusion status on mortality in acute heart failure. Circ Heart Fail. 2021;14(3):e007347. https://doi.org/10.1157/circheartfailure.120.007347.

26. Reichart D, Magnusson C, Zeller T, Blankenberg S. Dilated cardiomyopathy: from epidemiologic to genetic phenotypes: a translational review of current literature. J Intern Med. 2019;286(4):362–72. https://doi.org/10.1111/joim.12944.

27. Kavoluniene A, Vaitiekienė A, Cesnaite G. Congestive hepatopathy and hypoxic hepatitis in heart failure: a cardiologist's point of view. Int J Cardiol. 2013;166(3):534–8. https://doi.org/10.1016/j.ijcard.2012.05.003.

28. Koehnede Gonzalez AK, Lefkowitch JH. Heart disease and the liver: pathologic evaluation. Gastroenterol Clin N Am. 2018;47(2):241–55. https://doi.org/10.1016/j.gtc.2017.01.012.

29. Turnage RH, Kadesky KM, Myers SI, Guice KS, Oldham KT. Hepatic hypoperfusion after intestinal reperfusion. Surgery. 1996;119(2):151–60. https://doi.org/10.1016/s0039-6060(96)80163-2.

30. Jakob SM, Tenhunen JI, Laitinen S, Heino A, Alhava E, Takala J. Effects of systemic arterial hypoperfusion on splanchic hemodynamics and hepatic arterial buffer response in pigs. Am J Physiol Gastrointest Liver Physiol. 2001;280(5):G819–27.

31. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med. 1997;336(19):1350–5. https://doi.org/10.1097/00001883-199709240-00244.

32. Niuzzi V, Cannatà A, Manca P, Castrichini M, Barbati G, Aleksova A, et al. Atrial fibrillation in dilated cardiomyopathy: outcome prediction from an observational registry. Int J Cardiol. 2021;323:140–7. https://doi.org/10.1016/j.ijcard.2020.08.062.

33. Wiese S, Hove JD, Bendtsen F, Møller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol. 2014;11(5):177–86. https://doi.org/10.1038/nrgastro.2013.210.

34. Nuzzi V, Cannatà A, Manca P, Castrichini M, Barbati G, Aleksova A, et al. Cardiohepatic interactions in heart failure: an overview and clinical
implications. J Am Coll Cardiol. 2013;61(24):2397–405. https://doi.org/10.1016/j.jacc.2013.03.042.

50. Kato T, Nizuma S, Inuzuka Y, Kawashima T, Okuda J, Kawamoto A, et al. Analysis of liver metabolism in a rat model of heart failure. Int J Cardiol. 2012;161(3):130–6. https://doi.org/10.1016/j.ijcard.2011.07.056.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.